GLPBio

Signaling Pathways

Research Area, Signaling Pathways | GlpBio Life Science Products Suppliers

Read More about this category

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Research Areas

Products Related to Signaling Pathways(40594)

  • GC81511 structure
    GC81511BCN-CE-phosphoramidite
    CAS: 1393524-83-8
    Purity: >96.00%

    BCN-CE-phosphoramidite is an oligonucleotide modifier containing a BCN strained cyclooctyne structure.

  • GC81512 structure
    GC81512dCDK9-202
    Purity: >98.50%

    dCDK9-202 is a CDK9 PROTAC degrader with a DC 50 of 3.5 nM.

  • GC81513 structure
    GC81513SMARCA2/4-ligand-8
    CAS: 2380272-41-1
    Purity: >99.50%

    SMARCA2/4-ligand-8 is a SMARCA2/4 ligand, which can be used for the synthesis of PROTACs, such as PROTAC SMARCA2/4-degrader-26 [1] .

  • GC81514 structure
    GC81514PROTAC SMARCA2 degrader-35
    CAS: 3032998-97-0
    Purity: >98.00%

    PROTAC SMARCA2 degrader-35 (Compound 43) is a selective SMARCA2 PROTAC degrader with a DC 50 < 0.1 μM for SMARCA2.

  • GC81515 structure
    GC81515BMS-986482
    CAS: 3062993-48-7
    Purity: >98.00%

    BMS-986482 is a CRBN -mediated IKZF1-4 ( Ikaros family zinc finger 1-4 ) molecular glue degrader.

  • GC81516 structure
    GC81516BMS-986482 acetate
    Purity: >98.00%

    BMS-986482 acetate is a CRBN -mediated IKZF1-4 ( Ikaros family zinc finger 1-4 ) molecular glue degrader.

  • GC81517 structure
    GC81517(Rac)-BMS-986449
    Purity: >99.00%

    (R)-BMS-986449 is the racemic mixture of BMS-986449.

  • GC81519 structure
    GC81519SHP1-IN-2
    Purity: >97.00%

    SHP1‑IN‑2 is a selective and orally active SHP1 inhibitor.

  • GC81520 structure
    GC81520Cinflumide
    CAS: 64379-93-7
    Purity: >99.50%

    Cinflumide is an orally active muscle relaxant.

  • GC81521 structure
    GC815212',3'-ddA(N-Bz) Phosphoramidite
    Purity: >98.00%

    2',3'-ddA(N-Bz) Phosphoramidite is a modified phosphoramidite monomer that can be used for the synthesis of oligonucleotides.

  • GC81522 structure
    GC81522WWZ-11-098
    Purity: >98.00%

    WWZ-11-098 is a selective CDK6 PROTAC degrader with DC 50 of 2.6 nM.

  • GC81523 structure
    GC8152317-Bromoheptadecanoic acid
    CAS: 13099-35-9
    Purity: >98.00%

    17-Bromoheptadecanoic acid is a PROTAC linker that can be used in the synthesis of PROTACs.

  • GC81524 structure
    GC81524Beruzatatug
    CAS: 2948329-71-1
    Purity: >99.00%

    Beruzatatug (BNT326/YL202 Antibody) is an IgG1 monoclonal antibody against HER3.

  • GC81525 structure
    GC81525(1R,9S)-Dxd
    CAS: 2766786-58-5
    Purity: >98.00%

    (1R,9S)-Dxd is an isomer of (Dxd).

  • GC81526 structure
    GC81526Delpacibart zotadirsen
    CAS: 2929240-20-8
    Purity: >92.50%

    Delpacibart zotadirsen (Del-zota), an antibody oligonucleotide conjugate (AOC), consists of a monoclonal antibody (Delpacibart) that binds to the transferrin receptor 1 (TfR1) conjugated to a phosphorodiamidate morpholino conjugate (PMO), Delpacibart zotadirsen is designed to deliver phosphorodiamidate morpholino oligomers (PMOs) to skeletal muscle and heart tissue to specifically skip exon 44 of the dystrophin gene and enable production of near-full length dystrophin.

  • GC81527 structure
    GC81527Sofetabart
    CAS: 3066905-22-1
    Purity: >98.00%

    Sofetabart (LY-4170156 Antibody) is a humanized IgG1 antibody that specifically targets folate receptor α ( FRα ).

  • GC81528 structure
    GC81528(5-Cl)-Exatecan TFA
    Purity: >98.00%

    (5-Cl)-Exatecan TFA is a derivative of Exatecan and a DNA topoisomerase inhibitor.

  • GC81529 structure
    GC81529ZW-191
    Purity: >98.00%

    ZW-191 is an antibody-drug conjugate (ADC) targeting folate receptor α (FRα).

  • GC81530 structure
    GC81530Elfetabart drozuntecan
    CAS: 3061153-84-9
    Purity: >98.00%

    Elfetabart drozuntecan (DB-1311; BNT324) is an antibody-drug conjugate ( ADC ) targeting B7H3.

  • GC81531 structure
    GC81531PBX-7016
    CAS: 3003834-34-9
    Purity: >98.00%

    PBX-7016 is a DNA topoisomerase I inhibitor and DDX5 degrader.

  • GC81532 structure
    GC81532Auristatin S TFA
    Purity: >99.00%

    Auristatin S TFA is a potent Auristatin payload.

  • GC81533 structure
    GC81533PE-E2K
    CAS: 3105822-56-5
    Purity: >98.00%

    PE-E2K is a derivative of Eribulin and can be used as an ADC toxin molecule [1] .

  • GC81534 structure
    GC81534MMA-NODAGA TFA
    Purity: >98.00%

    MMA-NODAGA TFA is a chelator for site-specific labeling of targeting proteins containing unpaired cysteine.

  • GC81535 structure
    GC81535Etedesiran
    Purity: >93.00%

    Etedesiran is a component of the AOC drug Delpacibart etedesiran, formed by the reaction of an siRNA that induces cleavage of mRNA encoding myotonic dystrophy protein kinase (MTPK or DMPK ) with SMCC linker.